skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Voxtalisib (Code C71704)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Voxtalisib

Definition: An orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Voxtalisib inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in susceptible tumor cell populations. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion in response to nutrient and energy deprivation. Accordingly, this agent maybe more potent compared to an agent that inhibits either PI3K kinase or mTOR kinase alone.

Display Name: Voxtalisib

Label: Voxtalisib

NCI Thesaurus Code: C71704 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2348352  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)

External Source Codes: 
PDQ Closed Trial Search ID 558907
PDQ Open Trial Search ID 558907 (check for NCI PDQ open clinical trial info)
UMLS CUI C2348352

Other Properties:
     Name Value (qualifiers indented underneath)
code C71704
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Dual_Kinase_Inhibitor_XL765
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom